| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Human Endogenous Metabolite
SY-640's primary action is hepatoprotective, though its specific molecular target has not been definitively identified in the available literature. As an acetamide analogue, it may interact with cellular pathways involved in liver protection. The compound attenuates liver injury induced by inflammatory stimuli, suggesting it may target inflammatory signaling pathways or modulate immune cell infiltration into the liver. Further mechanistic studies are needed to identify its precise molecular target. |
|---|---|
| ln Vitro |
SY-640 reduces the quantity of cells that invade the liver and lessens the elevation in leukocyte function-associated antigen-1 expression on these cells[1].
In vitro activity of SY-640 has been characterized through its ability to reduce the quantity of cells that invade the liver and lessen the expression of antigens on these cells. These findings suggest that SY-640 modulates immune cell function and inflammatory responses in the liver. The compound's defined structure and stability make it suitable for in vitro studies exploring cellular signaling pathways and receptor interactions. Specific in vitro potency data (e.g., IC50 values) are not detailed in the available literature. |
| ln Vivo |
Although a single dosage has little impact, SY-640 (oral; 150 mg/kg; once daily for 7 days) effectively reduces liver injury produced by lipopolysaccharide and Propionibacterium acnes[1]. In mice, SY-640 (po; 150 mg/kg; once daily for three days) dramatically raises the amount of liver microsomal cytochrome P-450 and the activity of aminopyrine demethylase. Two hours after oral SY-640 treatment, there is a clear inhibition of the hepatic microsomal aminopyrine demethylase activity[2].
In vivo, SY-640 attenuates Propionibacterium acnes- and lipopolysaccharide (LPS)-induced liver injury in mice. This protective effect demonstrates its significant hepatoprotective activity in animal models of acute liver injury. The compound reduces the quantity of cells that invade the liver and lessens antigen-1 expression on these cells. These in vivo findings support the compound's potential for treating liver injury and inflammatory liver conditions, though further studies are needed to fully characterize its therapeutic efficacy. |
| Enzyme Assay |
In vitro enzyme/receptor binding experiments for SY-640 would typically involve screening the compound against a panel of receptors, enzymes, and ion channels to identify potential targets. Given its hepatoprotective activity, assays might focus on inflammatory mediators, oxidative stress markers, or liver-specific enzymes. Standard binding assays involve incubating the compound with target proteins and measuring displacement of labeled ligands or changes in enzymatic activity. However, specific experimental protocols for SY-640 are not detailed in the available literature.
|
| Cell Assay |
In vitro cellular assays for SY-640 would involve culturing hepatocytes or liver cell lines (e.g., HepG2, primary hepatocytes) and treating them with the compound, often followed by challenge with inflammatory stimuli such as LPS or cytokines. Endpoints include cell viability (MTT assay), measurement of inflammatory markers (TNF-α, IL-6), oxidative stress indicators, and assessment of apoptosis. These experiments characterize the compound's cytoprotective effects and mechanisms of action. Specific protocols and concentrations are not detailed in the available literature.
|
| Animal Protocol |
In vivo animal experiments for SY-640 have been conducted in mouse models of liver injury induced by Propionibacterium acnes and lipopolysaccharide (LPS). Mice are treated with SY-640 prior to or concurrently with the administration of inflammatory stimuli. Key endpoints include assessment of liver histopathology, measurement of liver enzyme levels (ALT, AST), quantification of inflammatory cell infiltration, and evaluation of antigen expression on infiltrating cells. These studies demonstrate the compound's hepatoprotective efficacy in vivo.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of SY-640 have not been extensively characterized in the available literature. As a small-molecule research compound, its absorption, distribution, metabolism, and excretion would need to be determined through standard PK studies. Such studies would involve administering the compound to animals (oral or intravenous), collecting plasma and tissue samples at various time points, and quantifying the compound and its metabolites by LC-MS/MS. Parameters such as Cmax, Tmax, AUC, half-life, and bioavailability would be determined in future studies.
|
| Toxicity/Toxicokinetics |
Toxicological information for SY-640 is not detailed in the available literature. As a research compound, its safety profile would need to be established through standard toxicology studies including acute, subacute, and chronic toxicity assessments in animal models. The compound's hepatoprotective activity suggests it may have a favorable safety profile in the liver, but comprehensive toxicology data are required for any therapeutic development. For research use, standard laboratory safety practices are sufficient.
|
| References |
|
| Additional Infomation |
SY-640 is a synthetic research compound with demonstrated hepatoprotective effects in animal models of liver injury. It is an acetamide analogue that attenuates Propionibacterium acnes- and lipopolysaccharide-induced liver injury in mice. The compound reduces liver-infiltrating cell numbers and decreases antigen-1 expression on these cells. SY-640 is not a drug and has no clinical trials or approved therapeutic indications. It is available for research use only, serving as a tool compound for studying liver protection and inflammatory mechanisms.
|
| Molecular Formula |
C11H13NO3
|
|---|---|
| Molecular Weight |
207.23
|
| Exact Mass |
207.089
|
| CAS # |
168705-70-2
|
| PubChem CID |
9837165
|
| Appearance |
Light yellow to yellow liquid
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
349.2±21.0 °C at 760 mmHg
|
| Flash Point |
165.0±22.1 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.557
|
| LogP |
0.89
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
15
|
| Complexity |
244
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(N(CC1=CC=C2OCOC2=C1)C)(=O)C
|
| InChi Key |
JIWDGIYBLGMPRV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H13NO3/c1-8(13)12(2)6-9-3-4-10-11(5-9)15-7-14-10/h3-5H,6-7H2,1-2H3
|
| Chemical Name |
N-(1,3-benzodioxol-5-ylmethyl)-N-methylacetamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (482.56 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (12.06 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.8256 mL | 24.1278 mL | 48.2556 mL | |
| 5 mM | 0.9651 mL | 4.8256 mL | 9.6511 mL | |
| 10 mM | 0.4826 mL | 2.4128 mL | 4.8256 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
